Current drug delivery · 2026
Lansoprazole/β-Cyclodextrin-Based Metal-Organic Frameworks: Development, Characterization, and Anti-Ulcer Activity Evaluation on Rats.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Alsulays Bader B
Аннотация
INTRODUCTION: Gastric ulcers are among the most common diseases worldwide, affecting individuals of all ages and genders. Lansoprazole (LNS) is one of the first-choice treatments for ulcers. In this study, β-Cyclodextrin-based metal-organic frameworks (β-CD-MOFs), which have recently attracted attention for biomedical applications, were used as carriers for LNS to enhance its physicochemical properties.
METHODS: β-CD-MOF crystals were prepared, and LNS was successfully loaded into the crystals in the presence of MgO. Pure LNS and the formulation were characterized using Differential Scanning Calorimetry (DSC), Powder X-Ray Diffraction (PXRD), Fourier-Transform Infrared spectroscopy (FTIR), Scanning Electron Microscopy (SEM), and in vitro release studies. The anti-ulcer activity was evaluated in male Wistar albino rats.
RESULTS: Dissolution studies revealed that approximately 90% of LNS was released from the formulation within 60 minutes, and the formulation's color remained unchanged after exposure to light. The formulation demonstrated a significant reduction in mucosal erythema and mucosal surface lesions, as well as a higher percentage of ulcer index inhibition.
DISCUSSION: Loading of LNS into β-CD-MOF enhanced its release and photostability. In vivo studies suggest that the formulation has a potent anti-ulcerogenic capability comparable to that of LNS.
CONCLUSION: β-CD-MOF, a promising carrier in drug delivery, improves the properties of LNS and further enhances its anti-ulcer activity.
METHODS: β-CD-MOF crystals were prepared, and LNS was successfully loaded into the crystals in the presence of MgO. Pure LNS and the formulation were characterized using Differential Scanning Calorimetry (DSC), Powder X-Ray Diffraction (PXRD), Fourier-Transform Infrared spectroscopy (FTIR), Scanning Electron Microscopy (SEM), and in vitro release studies. The anti-ulcer activity was evaluated in male Wistar albino rats.
RESULTS: Dissolution studies revealed that approximately 90% of LNS was released from the formulation within 60 minutes, and the formulation's color remained unchanged after exposure to light. The formulation demonstrated a significant reduction in mucosal erythema and mucosal surface lesions, as well as a higher percentage of ulcer index inhibition.
DISCUSSION: Loading of LNS into β-CD-MOF enhanced its release and photostability. In vivo studies suggest that the formulation has a potent anti-ulcerogenic capability comparable to that of LNS.
CONCLUSION: β-CD-MOF, a promising carrier in drug delivery, improves the properties of LNS and further enhances its anti-ulcer activity.